home / stock / pgen / pgen news

PGEN News and Press, Precigen Inc. From 08/17/23

Stock Information
Company Name: Precigen Inc.
Stock Symbol: PGEN
Market: NASDAQ
Website: precigen.com
Menu
PGEN PGEN Quote PGEN Short PGEN News PGEN Articles PGEN Message Board
Get PGEN Alerts

News, Short Squeeze, Breakout and More Instantly...
PGEN - 10 Top Penny Stocks To Buy According To Insiders In August

2023-08-17 12:16:09 ET Engaging in the world of low-cost stocks often referred to as penny stocks , is appealing to those looking to capitalize on the potential upsides of the stock market. These stocks, priced below $5, are known for their intrinsic risk. They’re also known for ...
PGEN - LGHL and EBIX among mid-day movers

2023-08-10 13:25:55 ET Gainers: WeWork ( WE ) +87% . Capri Holdings Limited ( CPRI ) +56% . Black Spade Acquisition ( BSAQ ) +58% . Edible Garden AG Incorporated ( EDBL ) +43% . Lion Group Holding Ltd. ( LGHL ) +37% . Precige...

PGEN - LifeMD, Precigen top healthcare gainers; Galera, Virios lead losers' pack

2023-08-10 10:27:32 ET Gainers: LifeMD ( LFMD ) +20% . Precigen ( PGEN ) +19% . Repare Therapeutics ( RPTX ) +16% . Cosmos Health ( COSM ) +13% . GoodRx Holdings ( GDRX ) +13% . Losers: Galera Therapeutics ( GRTX ) -...

PGEN - Precigen, Inc. (PGEN) Q2 2023 Earnings Call Transcript

2023-08-09 15:03:06 ET Precigen, Inc. (PGEN) Q2 2023 Earnings Conference Call August 09, 2023 08:30 AM ET Company Participants Steve Harasym - Vice President, Investor Relations Helen Sabzevari - President & Chief Executive Officer Harry Thomasian - Chief Fin...
PGEN - Precigen Phase 1/2 trial selected as a pivotal study for rare disease therapy

2023-08-09 15:01:02 ET More on Precigen Unraveling The Promise Of Precigen: Biotech Innovations Amid Financial Challenges Precigen gains on FDA Breakthrough Therapy Designation Precigen gets IND clearance for phase 2 trial of cervical cancer immunotherapy Pre...

PGEN - Precigen GAAP EPS of -$0.08 beats by $0.02, revenue of $1.77M misses by $0.41M

2023-08-09 08:02:24 ET Precigen press release ( NASDAQ: PGEN ): Q2 GAAP EPS of -$0.08 beats by $0.02 . Revenue of $1.77M (-39.2% Y/Y) misses by $0.41M . Cash, cash equivalents, short-term and long-term investments totaled $95.6 million as of June 30, 2023; cash...

PGEN - Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025

Precigen Reports Second Quarter and First Half 2023 Financial Results and Provides Update on Portfolio Prioritization and Capital Allocation Strategies to Extend Projected Cash Runway into 2025 PR Newswire – The FDA confirmed that the ongoing Phase 1/2 single arm study ...
PGEN - Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval

Precigen Announces FDA Confirmation that the Ongoing Phase 1/2 Study of PRGN-2012 AdenoVerse Immunotherapy Will Serve as the Pivotal Study to Support Accelerated Approval PR Newswire – FDA confirmed that the ongoing Phase 1/2 single arm study will serve as pivotal and n...

PGEN - Precigen Q2 2023 Earnings Preview

2023-08-08 12:44:42 ET Precigen ( NASDAQ: PGEN ) is scheduled to announce Q2 earnings results on Wednesday, August 9th, before market open. The consensus EPS Estimate is -$0.10 and the consensus Revenue Estimate is $2.18M (-25.1% Y/Y). For further details see: Pr...

PGEN - Notable earnings before Wednesday's open

2023-08-08 10:46:10 ET Major earnings expected before the bell on Wednesday include: Brookfield Asset Management ( BAM ) 3D Systems ( DDD ) PENN Entertainment ( PENN ) Roblox ( RBLX ) Sony Group ( SONY ) For further details see: Notable ea...
Previous 10 Next 10